Bristol-Myers Squibb

bms.com

Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious and life-threatening diseases. Our medicines are helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience, fibrosis and others.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ARRAY BIOPHARMA AND BRISTOL-MYERS SQUIBB ANNOUNCE STRATEGIC COLLABORATION

Bristol-Myers Squibb | May 30, 2017

news image

Array BioPharma (Nasdaq:ARRY) and Bristol-Myers Squibb Company (NYSE:BMY) today announced the companies have entered into a clinical research collaboration to investigate the safety, tolerability and efficacy of Array's investigational MEK inhibitor, binimetinib in combination with Bristol-Myers Squibb's Opdivo (nivolumab) and Opdivo Yervoy (ipilimumab) regimen as a potential treatment for metastatic colorectal cancer in patients with microsatellite stable tumors....

Read More

BRISTOL-MYERS SQUIBB TO ACQUIRE IFM THERAPEUTICS TO STRENGTHEN ONCOLOGY PIPELINE FOCUS ON INNATE IMMUNITY

World Pharma News | August 03, 2017

news image

Bristol-Myers Squibb Company and IFM Therapeutics (IFM) announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of IFM Therapeutics, a venture-backed biotech company focused on developing therapies that modulate novel targets in the innate immune system to treat cancer, autoimmunity and inflammatory disorders. The acquisition will give Bristol-Myers Squibb full rights to IFM’s preclinical STING (stim...

Read More

BAD NEWS FOR INNATE PHARMA AS BMS-BACKED DRUG STUMBLES

Bristol-Myers Squibb | November 23, 2017

news image

French biotech Innate Pharma says it can’t see a development path forward for its lead cancer drug lirilumab after another clinical trial miss. The Bristol-Myers Squibb-partnered checkpoint inhibitor, licensed in a $465m deal in 2011....

Read More

WHO DO YOU TRUST? FOR DOCTORS, IT'S BRISTOL-MYERS SQUIBB AND BIOGEN

fiercepharma | May 09, 2018

news image

When it comes to pharma partners, doctors prefer quality digital content. While that makes sense, new research shows that it also fosters trust with U.S. physicians.For the first time, DRG Digital’s Manhattan Research queried doctors about which pharma companies they trust in its annual Taking the Pulse survey. They asked a range of questions about those that have quality content, empathy for healthcare providers and a patients-first motivation. However, it was credible scientific content ...

Read More
news image

ARRAY BIOPHARMA AND BRISTOL-MYERS SQUIBB ANNOUNCE STRATEGIC COLLABORATION

Bristol-Myers Squibb | May 30, 2017

Array BioPharma (Nasdaq:ARRY) and Bristol-Myers Squibb Company (NYSE:BMY) today announced the companies have entered into a clinical research collaboration to investigate the safety, tolerability and efficacy of Array's investigational MEK inhibitor, binimetinib in combination with Bristol-Myers Squibb's Opdivo (nivolumab) and Opdivo Yervoy (ipilimumab) regimen as a potential treatment for metastatic colorectal cancer in patients with microsatellite stable tumors....

Read More
news image

BRISTOL-MYERS SQUIBB TO ACQUIRE IFM THERAPEUTICS TO STRENGTHEN ONCOLOGY PIPELINE FOCUS ON INNATE IMMUNITY

World Pharma News | August 03, 2017

Bristol-Myers Squibb Company and IFM Therapeutics (IFM) announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of IFM Therapeutics, a venture-backed biotech company focused on developing therapies that modulate novel targets in the innate immune system to treat cancer, autoimmunity and inflammatory disorders. The acquisition will give Bristol-Myers Squibb full rights to IFM’s preclinical STING (stim...

Read More
news image

BAD NEWS FOR INNATE PHARMA AS BMS-BACKED DRUG STUMBLES

Bristol-Myers Squibb | November 23, 2017

French biotech Innate Pharma says it can’t see a development path forward for its lead cancer drug lirilumab after another clinical trial miss. The Bristol-Myers Squibb-partnered checkpoint inhibitor, licensed in a $465m deal in 2011....

Read More
news image

WHO DO YOU TRUST? FOR DOCTORS, IT'S BRISTOL-MYERS SQUIBB AND BIOGEN

fiercepharma | May 09, 2018

When it comes to pharma partners, doctors prefer quality digital content. While that makes sense, new research shows that it also fosters trust with U.S. physicians.For the first time, DRG Digital’s Manhattan Research queried doctors about which pharma companies they trust in its annual Taking the Pulse survey. They asked a range of questions about those that have quality content, empathy for healthcare providers and a patients-first motivation. However, it was credible scientific content ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us